David P. Meeker, M.D. is the CEO and Chairman of Rhythm Pharmaceuticals, Inc., a company focused on developing treatments for rare genetic diseases tied to obesity. With an M.D. from the University of Vermont and an Advanced Management Program completion...
David P. Meeker, M.D. is the CEO and Chairman of Rhythm Pharmaceuticals, Inc., a company focused on developing treatments for rare genetic diseases tied to obesity. With an M.D. from the University of Vermont and an Advanced Management Program completion at Harvard Business School, Dr. Meeker brings a strong background in medicine and leadership to the role. He has over 25 years of experience in the biotech and pharmaceutical sectors, having served as the former CEO of Genzyme, overseeing key developments in rare diseases and multiple sclerosis treatments. He has been part of the Rhythm team since July 2023 and has also held various high-level positions within large pharmaceutical companies. Under his leadership, the company is dedicated to creating valuable therapies, reflecting both innovation and a deep understanding of patient needs. Dr. Meeker's practical approach integrates medical knowledge with business strategy, driving significant growth and advancements in how we treat obesity-related health issues.